Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States

Findings suggest that among treatment attributes assessed, the most important attributes for CLL/SLL patients were impact of atrial fibrillation on QoL, PFS, and impact of headache on QoL. Shared decision-making in treatment selection should include informed discussion about efficacy and impact of AEs on QoL.